Inozyme Pharma (INZY) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Inozyme Pharma (INZY – Research Report), ...
Merus price target lowered to $70 from $73 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Merus (MRUS) to $70 from $73 and keeps a Buy rating on the shares. The firm ...
Benzinga.com1y
Tazeen Ahmad's Stock Ratings
Tazeen Ahmad is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future ...
Hosted on MSN2mon
Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $60 from $58 and keeps a Neutral rating on the shares after the company pre-announced Q4 and FY24 ...
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
Seeking Alpha15d
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
we think SAGE is again trading on fundamentals,” BofA analyst Tazeen Ahmad wrote. With a $5 price target, Ahmad issued an underperform rating on SAGE, citing bleak commercial prospects for its ...